These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35556143)

  • 1. Comparing the Liver Safety Profiles of 4 Next-Generation CGRP Receptor Antagonists to the Hepatotoxic CGRP Inhibitor Telcagepant Using Quantitative Systems Toxicology Modeling.
    Woodhead JL; Siler SQ; Howell BA; Watkins PB; Conway C
    Toxicol Sci; 2022 Jun; 188(1):108-116. PubMed ID: 35556143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Investigations Support Liver Safety of Ubrogepant.
    Smith B; Rowe J; Watkins PB; Ashina M; Woodhead JL; Sistare FD; Goadsby PJ
    Toxicol Sci; 2020 Sep; 177(1):84-93. PubMed ID: 32579200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focus on zavegepant: the first intranasal third-generation gepant.
    Scuteri D; Tarsitano A; Tonin P; Bagetta G; Corasaniti MT
    Pain Manag; 2022 Nov; 12(8):879-885. PubMed ID: 36189708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
    Sinclair SR; Kane SA; Van der Schueren BJ; Xiao A; Willson KJ; Boyle J; de Lepeleire I; Xu Y; Hickey L; Denney WS; Li CC; Palcza J; Vanmolkot FH; Depré M; Van Hecken A; Murphy MG; Ho TW; de Hoon JN
    Br J Clin Pharmacol; 2010 Jan; 69(1):15-22. PubMed ID: 20078608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling.
    Woodhead JL; Pellegrini L; Shoda LKM; Howell BA
    Pharm Res; 2020 Jan; 37(2):24. PubMed ID: 31909447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists.
    Johnson KW; Li X; Huang X; Heinz BA; Yu J; Li B
    Headache; 2022 Jul; 62(7):848-857. PubMed ID: 35822594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
    Leung L; Liao S; Wu C
    ACS Chem Neurosci; 2021 Jul; 12(14):2629-2642. PubMed ID: 34184869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.
    Durham PL; Vause CV
    CNS Drugs; 2010 Jul; 24(7):539-48. PubMed ID: 20433208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atogepant: an emerging treatment for migraine.
    Rustichelli C; Avallone R; Ferrari A
    Expert Opin Pharmacother; 2022 Apr; 23(6):653-662. PubMed ID: 35319319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
    Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
    Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Oral Calcitonin-Gene-Related Peptide Antagonists for the Treatment of Acute Migraine: Updated Meta-analysis.
    Ha DK; Kim MJ; Han N; Kwak JH; Baek IH
    Clin Drug Investig; 2021 Feb; 41(2):119-132. PubMed ID: 33426614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.